Tissue-and tumour-selective targeting of murine leukemia virus-based replication-competent retroviral vectors by Metzl, Christian
1 
 
 
 
 
 
DIPLOMARBEIT 
Titel der Diplomarbeit 
Tissue- and Tumour-Selective Targeting 
of Murine Leukemia Virus-Based 
Replication-Competent Retroviral Vectors 
 
Band 1 von 1 
Verfasser 
Christian Metzl 
angestrebter akademischer Grad 
Magister der Naturwissenschaften (Mag.rer.nat.) 
Wien, 2012  
Studienkennzahl lt. Studienblatt: A 441 
Studienrichtung lt. Studienblatt: Diplomstudium Genetik-Mikrobiologie (Stzw) UniStG 
Betreuerin / Betreuer: Univ. Prof. Dr. Walter H. Günzburg 
 
2 
 
Abstract and aim (English) 
 
Replication-competent retroviral (RCR) vectors are very useful for cancer gene therapy, as 
they exhibit high infection efficiency and a certain degree of tumour selectivity. Improving 
tumour selectivity is nonetheless desirable, and this can be achieved by transcriptional 
targeting, whereby the promiscuous viral promoter is replaced by a tumour-selective one.  
It was the aim of this study to characterise one or several promoters which confer the desired 
cell selectivity and high levels of transgene expression onto an RCR vector, while retaining 
adequate genomic stability.  
Based on an extensive literature search, seven promoters were chosen, namely the cancer-
selective cellular Midkine, c-erbB-2 and AFP promoters, the cancer-selective synthetic CTP4 
promoter, the liver tissue-selective hybrid EII-Pa1AT promoter, as well as the promiscuous c-
fos promoter, whose usefulness as a promoter for retroviral vectors was to be evaluated, and 
the promiscuous viral mCMV promoter, which was used as a ubiquitously active control. In a 
preliminary experiment, the strength and cell selectivity of these promoters was evaluated in 
the context of an eGFP expression plasmid. The most promising of them, namely the CTP4, 
EII-Pa1AT and c-fos promoters, as well as the mCMV promoter, were then incorporated into 
a Murine Leukemia Virus - based RCR vector in two different ways: In one design, the entire 
MLV promoter was replaced by the heterologous promoters, whereas in the other design, the 
portion of the MLV promoter upstream of the TATA box was removed and replaced with the 
heterologous promoters lacking their TATA box. While a vector bearing the c-fos promoter 
replicated only poorly in cell culture, vectors containing the CTP4 and EII-Pa1AT promoters 
performed considerably better - but only in the latter design, in which the MLV TATA box was 
retained. These vectors exhibited transgene expression levels and replication kinetics similar 
to the parental vector, but in a cell-selective manner. Also, their genomic stability was on par 
with the parental vector, and their cell selectivity was retained over several repeated infection 
cycles. 
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The results of this research project were published in the Journal of Virology in 2006 (see 
chapter 3), with the focus on vectors bearing the CTP4 or EII-Pa1AT promoters. This thesis 
expands on this publication by addition of, amongst others, a more extensive introduction, 
presentation of preliminary results, and a description of further developments.  
 
 
Zusammenfassung und Zielsetzung (Deutsch) 
 
Replikationskompetente retrovirale (RCR) Vektoren sind für die Gentherapie sehr 
interessant, da sie eine hohe Infektionseffizienz und ein gewisses Maß an Tumorselektivität 
aufweisen. Dennoch ist es wünschenswert, die Tumorselektivität noch zu steigern, und das 
kann unter anderem durch transcriptional targeting erreicht werden. Hierbei wird der 
promiskuitive, d.h. in einer Vielzahl von Zelltypen aktive, virale Promoter durch einen 
tumorselektiven ersetzt.  
Das Ziel der vorliegenden Studie war es, einen oder mehrere Promotoren zu 
charakterisieren, die einem RCR Vektor starke Transgen-Expression und zellselektive 
Replikation verleihen, dabei aber die genomische Stabilität des Vektors nicht vermindern. 
Ausgehend von einer umfangreichen Literaturrecherche wurden sieben Promotoren 
ausgewählt, nämlich die krebsselektiven, zellulären Midkine, c-erbB-2 und AFP Promotoren, 
der krebsselektive, synthetische CTP4 Promotor, der Lebergewebe-selektive EII-Pa1AT 
Promotor, sowie der promiskuitive c-fos Promotor, dessen Nutzen als Promoter für 
retrovirale Vektoren evaluiert werden sollte, und der promiskuitive, virale mCMV Promotor, 
welcher als Kontrolle diente. Zuallererst wurde die Stärke der Genexpression und die 
Zellselektivität dieser Promotoren im Kontext eines eGFP-Expressionsplasmids evaluiert. Die 
vielversprechendsten Promotoren, nämlich die CTP4, EII-Pa1AT und c-fos Promotoren, 
sowie der mCMV Promotor, wurden danach in einen auf dem murinen Leukämievirus (MLV) 
basierenden RCR-Vektor inkorporiert, und zwar auf zwei verschiedene Arten: Entweder 
wurde der gesamte MLV Promotor durch den gesamten heterologen Promoter ersetzt, oder 
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es wurde nur ein Teil des MLV Promoters - bis zum 5' Ende der TATA Box - entfernt und 
durch den heterologen Promoter, dessen TATA Box entfernt worden war, ersetzt. Während 
sich ein Vektor unter Kontrolle des c-fos Promotors in Zellkultur nur kaum replizierte, lieferten 
Vektoren unter der Kontrolle des CTP4 oder EII-Pa1AT Promoters weit bessere Ergebnisse, 
allerdings nur, wenn die Promotoren auf die zuletztgenannte Weise, bei der die MLV TATA 
Box erhalten blieb, inkorporiert wurden. Diese Vektoren wiesen starke Transgen-Expression 
auf und eine Replikationskinetik, die dem parentalen Vektor entspricht, allerdings auf eine 
zellselektive Art und Weise. Auch ihre genomische Stabilität war der des parentalen Vektors 
ebenbürtig, und ihre Zellselektivität blieb auch nach mehreren Replikationsrunden erhalten. 
 
Die Ergebnisse dieses Forschungsprojekts wurden 2006 im Journal of Virology veröffentlicht 
(siehe Kapitel 3), wobei das Hauptaugenmerk auf den Vektoren lag, die den CTP4 oder den 
EII-Pa1AT Promotor enthielten. Diese Diplomarbeit erweitert diese Publikation um u.a. eine 
ausführlichere Einleitung, die Präsentation der Vorergebnisse, und eine Beschreibung der 
weiteren Entwicklung, nachdem dieses Projekt abgeschlossen war. 
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1 Introduction 
 
1.1 Gene therapy 
 
1.1.1 Basics of gene therapy 
Gene therapy is defined as the introduction of foreign genetic material into a patient’s cells in 
order to prevent or treat a disease. There are several types of gene therapy: 
• Gene therapy may be targeted to a selection of an individual’s somatic cells only 
(somatic gene therapy). This approach leads to mosaicism, in which the germline 
cells remain unaltered, and the newly inserted genes are not inherited by the 
patient’s offspring. The actual introduction of genetic material can be performed 
either ex vivo or in vivo. In the former case, target cells are first extracted from the 
patient, the genetic material is introduced, and the altered cells are then 
transplanted back into the target tissue. There, the altered cells either proliferate 
and outgrow their unaltered counterparts, or they secrete a desired gene product 
(Fig. 1a). This strategy can be employed to treat monogenetic, congenital 
diseases of the hematopoietic system (Gaspar HB, 2004) (Aiuti A, 2009). In an in 
vivo approach, gene therapeutical vectors are directly administered to resident 
cells in the patient’s target tissue (Fig. 1b).  
• Gene therapy may also be employed to alter an individual as a whole, in which 
case the treatment must be administered very early in life: Vectors may be 
injected into zygotes or early embryonic stages, or into sperm or egg cells. These 
strategies could be used to treat all kinds of monogenetic, hereditary diseases. 
Although such methods have already been employed to successfully generate 
transgenic primates (Smith KR, 2004), germline gene therapy in humans remains 
highly controversial and is in fact banned in many jurisdictions (Kimmelman J, 
2008). 
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Although naked DNA may be injected into target cells, usually a vector is employed. The 
most commonly used vectors are viruses, which, by their very nature, are very apt to 
introduce genes into cells. 
 
 
 
          A                                       B                                 C                                     D 
 
Fig. 1a   Ex vivo approach to gene therapy.  (A) Cells to be modified are extracted from patient. (B) 
Cells in culture are genetically altered. (C) Modified cells are selected for.  (D) Modified cells are 
administered to patient. 
 
 
  
 
 
1.1.2 Milestones of gene therapy development 
Although the concept of gene therapy was proposed as early as 1963 (Lederberg, 1963), it 
was not until 1989 that the first clinical trial involving gene therapy was performed 
(Rosenberg SA, 1990). Although clinical success remained elusive and there was already an 
ongoing debate about the ethical implications of gene therapy, there were no major setbacks 
(Gillet JP, 2009).  
Then, in a 1999 study, a patient died of a systemic inflammatory response, triggered by the 
administration of  large quantities of an adenoviral vector (Marshall E, 1999). In 2000, a 
Fig. 1b   In vivo approach to gene therapy. 
Foreign genetic material (most often contained 
in a vector) is administered to a patient. 
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widely publicised international gene therapy trial on X-linked severe combined 
immunodeficiency syndrome (SCID-X1) began (Cavazzana-Calvo M, 2000). SCID-X1 is a 
lethal immune deficiency affecting T, B, and natural killer (NK) cell development, and it is 
caused by mutations in the gene encoding for the common γ-chain of several interleukin 
receptors. The therapy involved transfer of the γ-chain gene into autologous, γ-chain 
deficient bone marrow cells, using an MLV vector in an ex-vivo approach. The therapy was 
successful, resulting in the sustained restoration of a functional adaptive immune system in 7 
out of the 10 involved patients. Another clinical trial in 2004 had similar results (Gaspar HB, 
2004). Two to six years after the procedure, however, 5 out of the total of 20 patients 
enrolled in these trials developed acute leukemia. One of these 5 patients died of this severe 
side effect (Hacein-Bey-Abina S, 2010). Investigation of these cases revealed that, in 4 out of 
5 patients, the vector integrated close to the LMO2 proto-oncogene, causing aberrant 
expression of LMO2 via retroviral enhancer activity (Hacein-Bey-Abina S, 2003). It was 
established that gammaretroviral vectors integrate preferentially near transcription start sites 
(Deichmann A, 2007), and a so-called high incidence region of vector integration was 
identified near exon 1 of LMO2 in T cells (Yamada K, 2009). However, other genetic 
abnormalities may need to be present for leukemia to arise (Howe SJ, 2008). 
Recently, an HIV-based self-inactivating vector for treatment for SCID-X1 has been 
developed, which was shown not to induce LMO2 expression in a mouse model (Zhou S, 
2010). 
Gene therapy was also employed to treat another type of SCID, namely SCID due to 
adenosine deaminase deficiency (ADA-SCID). ADA is an enzyme involved in purine 
metabolism, and its defectiveness leads primarily to impaired lymphozyte proliferation. As of 
2010, over 30 ADA-SCID patients had been treated by gene therapy, in most cases 
successfully (Ferrua F, 2010). In one trial, ten patients were treated using a protocol similar 
to the one employed in the aforementioned SCID-X1 trial, with a retroviral vector bearing the 
ADA gene. In eight of these patients, a functional immune system was restored. In contrast 
to the SCID-X1 trials, no patient developed a leukemia-like disorder (Aiuti A, 2002) (Aiuti A, 
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2009). It is hypothesised that the proliferation signal provided by the common γ-chain, in 
cooperation with deregulated expression of a proto-oncogene, favours the establishment of 
malignant cells. ADA, in contrast, confers no such proliferation signal (Kohn DB, 2009). 
Another study in 2006 was concerned with the treatment of X-linked chronic granulomatous 
disease (X-CGD), an immunodeficiency caused by mutations in gp91(phox), which leads to 
deficient antimicrobial activity in phagocytes. Two patients were treated with gammaretroviral 
vectors expressing gp91(phox), and the condition of these patients improved significantly 
during therapy. Similar to the SCID-X1 trials, the vectors often integrated next to one of three 
proto-oncogenes, namely the MDS1-EVI1, PRDM16 or SETBP1 genes, which led to a – 
beneficial – expansion of gene-corrected cells (Ott MG, 2006). After two years, however, a 
silencing of gp91(phox) expression occurred, as well as chromosomal rearrangements and 
myodysplasia due to oncogene expression. Eventually, one patient received a hematopoietic 
stem cell (HSC) transplant, whereas the other patient died of a severe sepsis, which was 
most likely a consequence of his underlying disease (European Society of Gene Therapy 
(ESGT), 2006) (Stein S, 2010). 
 
The world’s first commercial gene therapy product, Gendicine, was approved in China in 
2003. Gendicine is a recombinant, oncolytic adenovirus whose E1B transcriptional unit has 
been replaced by a human p53 expression cassette, and it is used against head- and neck 
tumours. English language literature on Gendicine appears to be scarce, but in 2005 it was 
reported that it has been administered to over 4000 patients, with encouraging results (Peng 
Z, 2005). Also in 2005, China approved a second gene therapy product, Ocorine (Shi J, 
2009). Also known as H101, this is an oncolytic adenovirus similar to Gendicine, but of lower 
toxicity (Huang PI, 2009). 
 
1.1.3 Cancer gene therapy 
Initially, gene therapy was directed at monogenetic hereditary diseases. Soon, however, it 
became clear that gene therapy can also be employed to combat vascular diseases, 
11 
 
infectious diseases such as AIDS and, most importantly, cancer. Up to 2007, over sixty 
percent of all gene therapy clinical trials performed were related to cancer (Edelstein ML, 
2007). The following list provides an overview over therapeutic genes and strategies 
investigated for their use in cancer gene therapy.  
• Tumour-suppressor genes can replace tumour suppressors no longer active in 
malignant cells. For instance, the re-establishment of p53 function has been 
considered a promising strategy (Kumar S, 2007). 
• Suicide genes lead to the death of tumour cells in which they are expressed, after 
the administration of a prodrug. The bystander effect, whereby nearby cells are 
also affected, constitutes an added advantage. 
• Some therapeutic genes, such as TNFα, are radiation-inducible. Others can be 
expressed under the control of a radiation-inducible promoter element. Ionising 
radiation can then be used to induce transgene expression at the right time and in 
the right tissue. 
• Drug resistance genes, transferred to certain types of normal cells such as HSCs, 
can protect them from the toxic effects of anticancer drugs. 
• RNA interference (RNAi) can be used to downregulate genes involved in the 
development or progression of cancer. 
• Angiogenic inhibitors impede the growth and dissemination of tumours. For 
example, several approaches are being investigated to block vascular endothelial 
growth factor (VEGF) signaling (Mae M, 2005) (Drevs J, 2000). 
• Genes expressing tumour antigens can be used for cancer vaccination. In animal 
models, success has been achieved using adenoviruses expressing tumour-
associated antigens (Akbulut H, 2006). 
• Autologous T cells can be engineered ex vivo and then transfused back into the 
patient. Most notably, such T cells can be transduced with a T cell receptor which 
confers specificity to a tumour antigen (Thomas S, 2007). 
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In most of these cases, the tumour cells are the actual targets of gene therapy. In contrast to 
gene therapy of hereditary enzymopathies, where it may be sufficient to transduce only a 
fraction of target cells, in cancer gene therapy it is desirable to transduce as high a 
proportion of tumour cells as possible (Vile RG, 2000). By necessity, the mode of application 
is in vivo, although local application may be possible, i.e. injecting the vector directly into the 
tumour. However, precautions to make sure that only tumour cells are transduced are 
advisable, especially when the therapeutic gene is a suicide gene. Vectors suitable for 
cancer gene therapy should therefore (1) allow for highly efficient transduction of target cells 
in a physiological (in vivo) environment, and (2) be selectively targeted to tumour cells. 
 
1.1.4 Main gene delivery systems 
The most commonly used vectors are adenoviruses and retroviruses. Other viruses 
employed include adeno-associated virus, simian virus 40, Herpes Simplex, vaccinia and 
poxvirus, as well as oncolytic viruses. In addition, there are delivery systems based on 
bacteria, lipofection or transfer of naked plasmid DNA (Edelstein ML, 2007). 
 
Adenoviral vectors 
The main advantages of adenoviral vectors are their high efficiency of transduction and high 
levels of - transient - gene expression. They infect cycling as well as quiescent cells. During 
the development of these vectors, more and more of the early transcription units have been 
deleted to render the viruses unable to replicate, to reduce immunogenicity and also to 
increase the transgene capacity. The latest generation of adenoviral vectors retains no more 
adenoviral coding sequences, and is produced using a helper virus (Kay MA, 2011). Aside 
from their high immunogenicity, one major problem associated with these vectors, especially 
in the field of cancer gene therapy, is their tropism: The most commonly used serotypes use 
the coxsackie-adenovirus receptor (CAR) for cell entry, which is not present on tumour cells. 
This problem could be circumvented by modifying the fiber proteins of the virus so that it can 
utilise other receptors (Sharma A, 2009). 
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Retroviral vectors 
Simple retroviruses, such as murine leukemia virus (MLV), are very well characterised. Their 
genomes contain only a small number of genes, none of which needs to be expressed for a 
virus to successfully infect a target cell. Therefore, a large proportion of the viral genome can 
be replaced with foreign DNA without compromising infectivity. The most prominent feature 
of retroviruses, however, is the ability to integrate into the chromosomal DNA of the host cell, 
where they can remain indefinitely in the form of proviruses. Because of this, retroviruses are 
suitable vectors when long-term expression of therapeutic genes needs to be achieved. In 
the case of most retroviruses, including MLV, integration into host DNA is only possible when 
the nuclear membrane is disassembled during mitosis (Yamashita M, 2006). Therefore, only 
proliferating cells can be transduced, which confers a certain degree of tumour selectivity to 
those retroviruses. Furthermore, retroviruses exhibit lower immunogenicity than other viral 
vectors (Xu L, 2007). 
Retroviral vectors can be used either in a replication-defective or replication-competent form. 
Replication-defective retroviruses (RDR) were the first to be developed because there was 
less chance that genes would be inserted in nontarget cells (Weber E, 2001). It has been 
shown, however, that the transduction efficiency of defective vectors is too low for 
widespread application in cancer gene therapy (Rainov NG, 2003). Replication-competent 
retroviral (RCR) vectors, which multiply in the infected tumour, could be capable of 
transducing a great number of tumour cells after an initial application of only a moderate 
amount of virus (Wang WJ, 2003). This could also alleviate the fact that retroviruses cannot 
be produced at high titres when compared with, for instance, adenoviruses (Rodrigues T, 
2007). Furthermore, their relatively short genome restricts the amount of transferable genetic 
material, and they exhibit poor diffusion in tissue. Because of the danger of insertional 
mutagenesis, it is imperative that RCR vector replication be as tightly restricted to tumour 
cells as possible. RCR vectors are also prone to losing the foreign genetic material following 
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extended replication cycles, since it is not essential for viral replication. Therefore, stability of 
the transgene is an issue which must be addressed. 
 
Lentiviral vectors 
Amongst the Retroviridae, lentiviruses possess the unique ability to transduce not only 
dividing, but also quiescent cells. This has facilitated their use as vectors for targeting cells of 
the nervous system, muscles, lungs, and liver (Gillet JP, 2009). The long period of lentiviral 
genome expression reduces the need for repeated injections. Another advantage is their 
relatively low immunogenicity (Han JJ, 1999). As with other retroviruses, however, their 
packaging capacity is comparatively small, and insertional mutagenesis also poses a 
potential problem (Mátrai J, 2010). 
A further development are “self-inactivating” (SIN) vectors, whereby a large portion of the 3’ 
U3 region, including the TATA box, is deleted. After reverse transcription, the LTRs of these 
vectors exhibit only little promoter or enhancer activity, and the expression of the transgene 
is driven by an internal promoter (Pauwels K, 2009). The reduced influence of these vectors 
on neighbouring cellular genes, such as proto-oncogenes, constitutes a key advantage 
(Modlich U, 2006). 
 
Nonviral delivery systems 
Although viral vectors are highly efficient gene vehicles, they suffer from certain 
disadvantages, such as toxicity or immunogenicity. Nonviral systems, in comparison, are less 
problematic in these respects, and also easier to prepare. 
The simplest nonviral delivery system is the transfer of naked plasmid DNA. Successful 
transfer of DNA has been reported for, amongst other organs, muscle, epidermis and liver, 
as well as solid tumours. However, because naked DNA is quickly degraded, low transfection 
efficiency has often been observed. (Gillet JP, 2009).  
To facilitate cell entry, DNA can be complexed with cationic lipids. The positively charged 
portion of these compounds binds to DNA, while the hydrophobic part interacts with the cell 
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membrane. Cationic lipids may also form micellar structures around DNA. These complexes 
are often internalised by endocytosis, and the DNA may be released into the cytoplasm by a 
rupturing endosome (Gillet JP, 2009). 
The main drawback of these chemical delivery systems is the lack of long-term transgene 
expression. This issue may be circumvented by addition of the SV40 or Epstein-Barr virus 
replicon to the vector, which turns the vector into a stable episome (Shibata MA, 2005). 
 
Various bacteria strains have been employed as gene delivery systems. For instance, an 
attenuated Salmonella strain expressing the E. coli cytosine deaminase gene has been used 
to treat solid tumours in a pilot clinical trial. The bacteria preferentially colonised the tumour 
site, and significant conversion of 5-fluorocytosin to 5-fluorouracil at the tumour site was 
observed (Nemunaitis J, 2003).   
 
Oncolytic viruses 
Not a gene delivery system per se, oncolytic viruses nevertheless hold promise for cancer 
therapy. They selectively replicate in and lyse tumour cells. Some viruses, such as 
Newcastle disease virus, naturally have this ability, whereas others, such as the adenovirus 
ONYX-15 (on which Gendicine is based), are engineered to target tumour cells (Gillet JP, 
2009). 
 
 
1.2 Retroviruses 
 
1.2.1 Structure 
Retroviruses are enveloped, with the lipid envelope taken from the producing cell upon 
budding. The envelope carries virus-encoded trans-membrane and surface glycoproteins, 
which are arranged as trimers and form spikes in the membrane. Beneath the envelope is a 
roughly spherical matrix, which surrounds the capsid. The capsid contains two copies of the 
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RNA genome, complexed with nucleocapsid proteins and smaller numbers of reverse 
transcriptase and integrase. Protease molecules are also present in the virion, although their 
location is uncertain (Fig. 2) (Coffin JM, 1997) (Knipe DM, 2007). 
 
 
 
Fig. 2   Retroviral structure. 
 
 
1.2.2 Genome 
The genomic organisation of retroviruses is in many ways unique. Most notably, they are the 
only truly diploid viruses, with the two RNA copies being held together by a "dimer linkage 
structure" at their 5’ ends. The two genome copies, each one 7 to 13 kb in size, are positive-
stranded and thus identical to the (full length) viral mRNA. Indeed, it has been shown that 
Rous Sarcoma Virus (RSV) packages RNAs that have previously been translated (LeBlanc 
JJ, 2004). In MLV, however, there is evidence for the existence of two distinct populations of 
full length RNA, one destined for protein synthesis, the other one for packaging (Butsch M, 
2002). Genomic RNA alone is not productively infectious, since, upon infection, the genome 
needs to undergo reverse transcription with the help of proteins present in the nucleocapsid. 
All retroviral genomes have at least 3 large coding domains, each one encoding a 
polyprotein: 
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• gag (group specific antigen): structural proteins of the matrix, capsid and 
nucleocapsid.  
• pol (polymerase): reverse transcriptase and integrase 
• env (envelope): envelope glycoproteins 
In addition, all retroviruses contain the small pro domain between gag and pol, coding for the 
viral protease. Complex retroviruses such as HIV also encode many "accessory genes" in 
addition to gag, pro, pol and env. Another  hallmark of retroviruses are the long terminal 
repeats (LTRs), direct repeats flanking the DNA form of the viral genome. Each LTR consists 
of the regions U3 (unique to the 3' end), R (repeated), and U5 (unique to the 5' end). They 
are thus called because in the RNA genome, U3 is missing at the 5' end and U5 at the 3' 
end, while R is present at both termini (Fig. 3) (Knipe DM, 2007). 
 
 
 
Fig. 3   Genomic organisation of simple retroviruses (Regions not to scale). 
 
 
1.2.3 Life cycle 
 
Cell entry 
The retroviral life cycle (Fig. 4) begins with the attachment of the virus to the cellular 
membrane. Initial binding is largely unspecific and has been shown to occur even with viral 
particles lacking Env proteins (Pizzato M, 1999). For virus entry, however, binding of viral 
surface proteins to one or several cellular receptors is necessary. Ecotropic MLV, for 
example, binds to the amino acid transporter mCAT-1. Most retroviruses then enter the cell 
by direct fusion of the envelope with the plasma membrane. MLV, however, appears to enter 
via an endocytic pathway (Katen LJ, 2001). Immediately after its release into the cytoplasm, 
the viral core commences a progressive disassembly known as uncoating. 
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Fig. 4   Retroviral life cycle. 
 
Reverse transcription 
With access to dNTPs, reverse transcription of the viral RNA genome into its DNA form takes 
place. It is noteworthy that reverse transcription already starts in free viral particles, using 
dNTPs which were taken along from the producing cell upon budding (Zhang H, 1993).  
Reverse transcription is initiated at a cellular tRNA primer, which was taken from the 
producing cell and is bound to a primer binding site (PBS) close to the 5' end of the viral 
genome. MLV generally utilises a tRNAPro molecule, although a certain degree of flexibility in 
the choice of primer has been observed (Lund AH, 2000). Reverse transcriptase elongates 
the primer up to the 5' end of the viral RNA, creating the so-called minus strand strong stop 
DNA. Because reverse transcriptase has RNaseH activity, the RNA strand complementary to 
the newly synthesised DNA strand is degraded. During the first translocation, the minus 
strand strong stop DNA is transferred to the 3' end of the viral genome, where it binds with its 
R region to the complementary R region of the RNA genome. This first translocation can be 
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intra- or intermolecular. In the latter case, both RNA copies are used to generate the reverse 
transcribed genome; if these copies are differing in sequence, a mutated virus can arise. 
Following the first translocation, elongation of the DNA strand then proceeds to the end of 
the RNA genome, which is simultaneously degraded. A short stretch of RNA, the polypurine 
tract (PPT), survives degradation and its 3' end serves to prime the synthesis of the plus 
strand strong stop DNA. During this process, the sequence complementary to the PBS in the 
tRNA primer is also transcribed and the tRNA is subsequently removed. In some 
retroviruses, such as lentiviruses, a second copy of the PPT near the centre of the genome is 
also used with high efficiency (Charneau P, 1992). In the second translocation, the PBS in 
the plus strand pairs with the complementary sequence in the minus strand to form a circular 
structure. Then, both strands are elongated to create a double-stranded DNA genome with 
complete LTRs (Fig. 5). 
20 
 
 
 
Fig. 5   Reverse transcription. 
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Integration 
The progressive uncoating eventually leads to the formation of a pre-integration complex 
(PIC), a fully reverse transcribed viral genome associated with viral proteins. The PIC is then 
translocated into the nucleus by various means. By an as yet uncertain route, lentiviral PICs 
are able to enter intact nuclei and thus infect non-dividing cells. However, the efficiency of 
transduction is comparatively low in G1 and especially G0 cells, presumably because the 
concentration of dNTPs in these cells is too low for reverse transcription to take place (Zack 
JA, 1990). Most other retroviruses, including MLV, have to wait for the disassembly of the 
nuclear membrane during cell division to gain access to the host genome. Catalysed by the 
viral integrase, and probably aided by other viral and even host factors (Suzuki Y, 2004), the 
viral genome is then integrated into host chromosomal DNA. Although integration is not 
sequence-specific, distribution of integration sites is not entirely random. HIV has a tendency 
to integrate in active transcription units, while MLV preferentially integrates in the vicinity of 
transcription start sites (Lewinski MK, 2006). The integrated provirus, which is physically 
indistinguishable from the surrounding DNA, is the only part of the virus necessary for the 
continuation of the viral life cycle.  
 
Gene expression 
Expression of viral genes is carried out entirely by the cellular genetic machinery. In most 
retroviruses, all viral coding regions are transcribed from a single promoter, situated in the 
U3 region of the 5' LTR. Transcription gives rise to a large primary transcript, encompassing 
the entire provirus from the transcription start site (TSS) at the 5' end of the 5' R region, to 
the 3' end of the 3' R region. This transcript can be processed to become a full length mRNA, 
or spliced to give rise to shorter, subgenomic RNAs, from which the various viral proteins are 
translated. Complex retroviruses form several subgenomic RNAs from which their accessory 
proteins are translated. In simple retroviruses, however, there are only 2 species of mature 
RNAs: 
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• Full-length RNA: This RNA is used for the synthesis of the Gag, Pro and Pol 
proteins. The 5’ UTR is relatively long and often contains additional AUG 
codons. In MLV, it is being suggested that an IRES is present near the start of 
the gag ORF, eliminating the need for the ribosome to scan the entire 5’UTR 
(Berlioz C, 1995) (Bolinger C, 2009). The amount of Gag proteins produced is 
10-20 times higher than the amount of Pro and Pol proteins. This is achieved 
by various means. In MLV, gag and pro-pol are in the same reading frame, but 
separated by a UAG codon. While this stop codon is utilised in most cases 
and translation termination occurs at the end of gag, in some cases 
termination suppression leads to the synthesis of the longer Gag-Pro-Pol 
polyprotein. This RNA also contains a packaging signal (Ψ) in its 5' portion, 
necessary for assembly of nucleocapsid proteins with genomic RNA. 
• Sub-genomic RNA: In this RNA species, a large portion of the genome 
encompassing the gag-pro-pol coding region is removed by splicing. This 
RNA serves for the translation of the Env precursor protein, which is 
synthesised at the rough endoplasmatic reticulum (RER), cleaved to form TM 
and SU proteins, and eventually incorporated into the plasma membrane. (Fig. 
6) 
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Fig. 6   Gene expression in MLV. (A) Integrated provirus. (B) Full-length RNA. (C) Gag and Gag-Pro-
Pol polyproteins translated from full-length RNA. (D) Subgenomic RNA. (E) Env polyprotein translated 
from subgenomic RNA. 
 
 
Assembly and budding 
In most retroviruses, including MLV, assembly of nascent virions is mediated by Gag. Gag 
proteins aggregate at the plasma membrane and associate with genomic RNA. Curvature is 
induced in the plasma membrane and the nascent virion buds out from the cell, taking with it 
a part of the membrane containing viral Env proteins. Nascent virions also contain a number 
of tRNA molecules, most importantly those which are used to prime reverse transcription. 
After release, maturation of the virions occurs by proteolytic cleavage of the Gag-Pro-Pol 
polyprotein, catalysed by Pro. 
 
 
  
Ψ 
Ψ 
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1.3 Strategies, vectors and promoters used in this study 
 
1.3.1 Transcriptional targeting and the ProCon vector system 
As mentioned above, retroviral vectors should ideally be targeted to tumour cells for use in 
cancer gene therapy. This can be achieved in two ways: In infection targeting, the virus is 
modified to preferentially infect the intended target cells, by modification or replacement of 
the viral surface glycoproteins. In transcriptional targeting, on the other hand, the spectrum of 
cell types which can be infected remains unaltered, but viral gene expression is restricted to 
target cells by using a cell-selective promoter. The choice of promoter is crucial. Cell-
selective mammalian promoters are usually several times weaker than their viral 
counterparts, while viral promoters usually do not offer the desired cell type selectivity. Of 
late, hybrid or synthetic promoters have been developed, which ideally combine high levels 
of expression with the desired cell selectivity (Hashimoto T, 2007) (Logg CR, 2002) (Kramer 
MG, 2003). Also, candidate promoters should be as small as possible because the capacity 
of the vector to carry foreign DNA is limited. 
The usage of a highly cell-selective promoter raises the problem that the promoter is most 
likely inactive in standard producing cells. This problem can be circumvented very elegantly 
by utilising the "promoter conversion" (ProCon) vector system (Fig. 7). An integrated provirus 
possesses two promoters: One in each U3 region of both LTRs. While both promoters may 
be active, only the one in the 5' U3 region drives expression of the viral genes. However, it is 
always the promoter in the 3' U3 region which is incorporated into nascent virions as part of 
their genomes. During reverse transcription, this promoter is copied to the 5' end and thus 
drives expression in newly infected cells. Barring mutations, the two promoters are identical 
in a normal viral life cycle. In ProCon vectors, on the other hand, two different promoters are 
used in the provirus that is to be expressed in producing cells: 
• The promoter in the 5' U3 region does not have to exhibit any cell selectivity, 
but it should offer high level expression in the intended producing cells. 
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Promiscuous viral promoters, such as the human cytomegalovirus (hCMV) 
immediate early promoter, may be used. 
• The promoter in the 3' LTR is the one which will be active in target cells, 
therefore it should be cell-selective. Activity of this promoter in producing cells 
is not necessary. 
 
Therefore, high levels of production can be achieved in any type of producing cell, of a vector 
that is nonetheless highly cell-selective (Saller RM, 1998). 
 
 
 
A 
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C 
 
 
 
Fig. 7   The ProCon vector system. (A) Provirus which gives rise to virions in producing cells. (B) RNA 
genome of nascent virions. (C) Integrated provirus in target cells. 
 
 
1.3.2 The retroviral vector ACE-GFP 
All vectors used in this study are derivatives of ACE-GFP, a replication competent, Moloney-
MLV based retroviral vector created by the group around Noriyuki Kasahara. A precursor of 
this vector was designed in 2000, using a novel approach to harbour the transgene.  In most 
earlier studies, the transgene had been placed in the 3’ U3 region, but this resulted in 
frequent recombination events and poor stability. Kasahara and coworkers fused the 
transgene to the 3’ end of the env gene instead, preceded by the encephalomyocarditis virus 
internal ribosome entry site (IRES). This design also allowed for the translation of the 
transgene from both full-length and subgenomic RNAs. The group then demonstrated that 
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this vector replicated efficiently in mammalian cell culture (Smith E, 2000). In 2001, using the 
enhanced green fluorescent protein (eGFP) as the transgene, they used this type of vector to 
efficiently transduce solid tumours in mice, and also demonstrated the genomic stability of 
this design over multiple serial infection cycles. Although the vector was not targeted in any 
way, there was no apparent spread outside the tumours. Non-tumour cells within the tumour 
mass were transduced, though, and the group also suspected that there might have been 
spread outside the tumours which has escaped detection (Logg CR, 2001). In 2002, 
therefore, they transcriptionally targeted this vector with a prostate cell-selective rat probasin 
(PB) promoter inserted in the 3' LTR, while the hCMV promoter in the 5' LTR drove 
expression in producing cells. In order to allow for the infection of non-murine cells, they 
pseudotyped the virus with the amphotropic 4070A Env protein, thus creating the vector 
ACE-GFP (Fig. 8). In an in vitro study, the group demonstrated that this vector allowed for 
high level expression of eGFP in a prostate cell selective manner. Their results also 
suggested that a hybrid promoter design was superior to a total replacement of the viral 
promoter: Vectors in which the heterologous promoter from its 5' end to the beginning if its 
TATA box was fused to the MLV TATA box exhibited greatly enhanced expression levels 
over vectors in which the entire viral promoter, up to the TSS, was removed. Their results 
also demonstrated that a strong promoter is needed to drive efficient virus replication (Logg 
CR, 2002). 
 
 
 
Fig. 8   The retroviral vector ACE-GFP, outfitted with a heterologous promoter. 
 
Since then, ACE-GFP - in its non-targeted form - has been the subject of further research. It 
was successfully used to transduce gliomas in athymic mice (Wang WJ, 2003) and hepatic 
metastases of colorectal tumours in immunocompetent mice (Hiraoka K, 2006), as well as 
murine and human orthotopic bladder tumours in mice (Kikuchi E, 2007). The vector was 
also used to express several suicide genes. Replacement of the eGFP gene with the yeast 
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cytosine deaminase (CD) gene gave rise to a vector which mediated efficient cell killing in 
gliomas of athymic mice (Tai CK, 2005) and the aforementioned bladder tumours. Similarly, 
the E. coli purine nucleoside phosphorylase (PNP) was successfully employed, also against 
bladder tumours (Kikuchi E, 2007 (2)) and gliomas (Tai CK, 2010), both in athymic mice. 
In a particularly interesting study, a predecessor to ACE-GFP was outfitted with an IgG 
binding site in the Env protein, and virions were complexed with anti-HER2 antibodies to 
target HER2 expressing cells in vitro. Although binding to target cells was efficient, cell entry 
was attenuated unless wild-type Env was coexpressed in the virions. This technique could be 
used to target an initial vector inoculum to the tumour, whereupon other targeting methods 
take over. Furthermore, this vector uses the relatively short VEGF IRES instead of the EMCV 
IRES (Tai CK, 2003). 
 
1.3.3 The mCMV IE promoter 
One of the most often utilised promoters in expression vectors is the human cytomegalovirus 
(hCMV) immediate early (IE) gene promoter. The strength of this promoter, though, varies 
greatly between species (Addison CL, 1997), which is reflected by the fact that hCMV infects 
only humans. Murine cytomegalovirus (mCMV), on the other hand, has a much broader host 
range and infects human as well as murine cells (Lafemina RL, 1988). Although there is no 
detectable sequence homology between hCMV and mCMV (Knipe DM, 2007), the 
organisation of their genomes in general and their IE promoters in particular is similar. The 
mCMV IE promoter contains several imperfect repeat elements, which are putative 
transcription factor binding sites (Dorsch-Häsler K, 1985). The two genes transcribed from 
this promoter, ie-1 and ie-3, encode transcriptional regulatory proteins (Liu XF, 2008). 
A comparison of the hCVM and the mCMV promoter in the context of a replication defective 
adenoviral vector was carried out by Addison and coworkers in 1997. They demonstrated 
that in human cells, the activity of the hCMV IE promoter is on par with the activity of the 
mCMV IE promoter, while in murine cells, the activity of the hCMV IE promoter is up to 100-
fold lower. They suggest that, when high levels of transgene expression need to be 
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achieved, which are ideally comparable between murine and human cells, the mCMV IE 
rather than the hCMV IE promoter should be employed (Addison CL, 1997). 
 
1.3.4 The EII-Pa1AT promoter 
This chimeric promoter, created by Gabriela Kramer and collaborators, consists of two liver 
cell-selective, rather than tumour-selective, elements:  
• The human α1-antitrypsin promoter (Pa1AT). α1-antitrypsin (AAT) is one of the 
major protease inhibitors in serum and expressed mainly in liver cells, but also in 
macrophages during inflammation (Tardiff J, 1998). In macrophages, however, 
the AAT gene is transcribed from a promoter other than Pa1AT.  
• The enhancer II (EII) of human hepatitis B virus (HBV). The EII is responsible for 
liver-selective transcription of the pregenomic 3.5 kb long HBV RNA that codes 
for the core proteins and serves as template for viral DNA synthesis (Yee JK, 
1989) 
Kramer and coworkers created several constructs using liver-selective cellular promoters 
alone, or in combination with liver-selective enhancers (Kramer MG, 2003). In vitro assays 
showed that the promoters alone exhibited significant cell selectivity, but poor expression 
levels. Constructs which combine these promoters with liver-selective enhancers exhibited 
varying strength; the highest activity, while retaining liver selectivity, was observed with the 
460 bp long EII-Pa1AT construct. The group then evaluated the in vivo performance of the 
enhancer-promoter combination constructs. In liver tissue, the EII-Pa1AT construct showed 
the highest activity of all liver-selective constructs tested, while in extrahepatic tissues, 
activity of EII-Pa1AT was much lower and similar to the other constructs. 
 
1.3.5 The CTP4 promoter 
This synthetic promoter consists of 10 T cell factor (TCF) binding sites fused to the TATA box 
of the adenovirus 5 E1B promoter (Ad5 E1B). It is selective for cells which are deregulated 
for β-catenin, which is the case in many tumours, especially those of colorectal origin. β-
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catenin is an important factor of the Wnt signaling pathway, which plays a fundamental role 
in embryonic development and adult homeostasis (Logan CY, 2004). In the absence of Wnt 
signaling, free cytoplasmatic β-catenin binds to a complex consisting of Axin, glycogen 
synthase kinase 3 (GSK3), casein kinase 1 (CK1) and the adenomatous polyposis coli (APC) 
protein. This complex phosporylates β-catenin and targets it for degradation. Binding of Wnt 
to its cellular receptor leads to inhibition of the aforementioned complex, which in turn causes 
free β-catenin to accumulate. Eventually it translocates into the nucleus and, together with 
the TCF/LEF family of proteins, activates Wnt target genes (MacDonald BT, 2009). β-catenin 
deregulation can be caused by a mutation in several of the involved proteins. Stabilising 
mutations in β-catenin are fairly frequent, but the most common cause of β-catenin 
accumulation, especially in colorectal cancers, are inactivating mutations in the APC protein 
(Waltzer L, 1999) (MacDonald BT, 2009). 
The group around Kai Lipinski constructed a promoter which contained 5 TCF binding sites, 
upstream of the minimal SV40 promoter (Lipinski KS, 2001). The promoter was then 
extensively optimised, especially with respect to the number of TCF binding sites, their 
distance from each other and to the TATA box, and the minimal promoter used. The resulting 
design, termed CTP4, was 380 bp in length and had a total of 10 TCF binding sites fused to 
a fragment encompassing the Ad5 E1B TATA box (Lipinski KS, 2004). In the context of an 
adenoviral vector, the CTP4 promoter exhibited equal or higher activity than the CMV 
promoter in β-catenin deregulated cells, but was virtually inactive in cells which are not β-
catenin deregulated. The group even suggests using this promoter in conjunction with 
directly toxic suicide genes such as diphtheria toxin A (DTA). 
 
1.3.6 The Midkine promoter 
Midkine (MK) is a heparin-binding growth factor, whose diverse functions include the 
promotion of growth, survival and migration of cells. It is normally expressed in a controlled 
manner during embryogenesis, while expression in adult normal tissues is severely limited.  
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Aberrant expression of MK is frequently observed in tumours, including hepatocellular 
carcinoma, colon carcinoma, neuroblastoma and breast cancers. The exact role of MK in 
tumorigenesis is not well understood, but it has been shown that the inhibition of MK 
expression in MK-positive tumours also inhibits their growth (Muramatsu T, 2010).  
Masatoshi Tagawa and coworkers explored the potential of the MK promoter for cancer-
selective expression of a transgene, employing it in the context of an adenoviral (Yu L, 2004) 
and an RDR (Miyauchi M, 2001) vector, both in in vitro and in mouse studies. The minimal 
promoter appears to be a 0.3 kb fragment, but it was a 0.6 kb fragment which conferred the 
highest difference of transgene expression between normal and immortalised cells 
(Sakiyama S, 2003). It was this 0.6 kb MK promoter that was used in the current study. 
 
1.3.7 The c-erbB-2 promoter 
The c-erbB-2 gene, also known as HER-2, encodes a tyrosine kinase receptor which is a 
member of the epidermal growth factor receptor family. c-erbB-2 is normally expressed at 
low levels in certain epithelial cells, but is overexpressed in about 30% of breast and ovarian 
cancers (Slamon DJ, 1989). Overexpression of c-erbB-2 leads to elevated tumorigenicity, 
enhanced metastatic potential, and a generally worse prognosis of the patients (Wang SC, 
2000).  
In their 2001 and 2002 studies, Tagawa and coworkers tested the ability of several c-erbB-2 
promoter fragments to drive the expression of a transgene in normal and breast cancer cell 
lines. They found that the minimal promoter responsible for tumour-selective transcription 
was contained in a 251 bp (-213/+38) fragment, while a 533 bp fragment conferred lower 
transcriptional activity and poorer cell selectivity, and a 124 bp fragment conferred no 
transgene transcription at all. The 22 base pairs at the 5´end of the 251 bp minimal promoter 
were shown to contain an element necessary for preferential activity in breast cancer cells 
(Maeda T, 2001) (Yu L, 2002). 
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1.3.8 The AFP promoter 
Alpha-fetoprotein (AFP) is an important component of fetal serum. It is produced in the fetal 
liver and yolk sac. AFP synthesis drops sharply immediately after birth, but is resumed in 
liver tumours and certain teratoblastomas, which is why AFP blood levels have become a 
widely used diagnostic marker for liver tumours. The expression of the AFP gene is regulated 
primarily at the level of transcription, by an upstream regulatory region consisting of a tissue-
selective promoter and several enhancers and silencers (Lazarevich, 2000). The AFP 
regulatory region thus holds great promise as a tool to target transgene expression to liver 
tumours. Since the proximal AFP promoter has been shown to be comparatively weak (Ido 
A, 1995), the large regulatory unit has been used in combination with stronger promoters in 
some studies (Cao G, 2000) (Cao G, 2001). As promoter length is critical in the context of a 
retroviral vector, the 0.3 kb proximal promoter, which has already been employed 
successfully in an adenoviral vector (Shi YJ, 2004), is used in the current study.  
 
1.3.9 The c-fos promoter 
c-fos belongs to the family of immediate early genes, which are activated quickly but 
transiently in response to intracellular signaling (Soloaga A, 2003). As a component of the 
AP-1 transcription factor, the c-fos gene product plays a role in cell differentiation and 
proliferation (Shaulian E, 2001), but also in tumorigenesis (Bakin AV, 1999) (Hu E, 1994). 
Although c-fos overexpression was reported to be associated with cancer (Gamberi G, 
1998), it may also have tumour-suppressor function (Teng CS, 2000), and the c-fos promoter 
is not generally regarded a cancer-selective one. It is, however, highly active and inducible 
by mitogenic stimuli or stress factors, which is why Manfred Wirth and coworkers 
investigated its usefulness as a promoter for mammalian expression vectors. They found that 
the 755 bp long c-fos promoter drove stronger transgene expression than the hCMV 
promoter in the majority of cell lines tested, and it can be induced up to 8-fold by addition of 
fetal calf serum (Bi JX, 2003). 
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2 Preliminary results 
 
2.1 Transcriptional activity of all heterologous promoters in various cell lines 
 
The tissue- or tumour-selective EII-Pa1AT (E2), AFP, CTP4, Midkine (MK) and c-erbB-2 
promoters were chosen as candidate promoters for targeted RCR vectors. In addition, RCR 
vectors under the control of the promiscuous mCMV and c-fos promoters were also 
generated, the former as a control, the latter because its utility as a strong, ubiquitously 
active promoter was to be investigated. 
 
Before the heterologous promoters were tested in the context of an RCR vector, their 
strength and cell selectivity was evaluated in a preliminary experiment. To this end, the 
promoters were inserted into the promoterless expression vector pEGFP1, upstream of the 
eGFP gene. Because expression of the retroviral vector is driven by the hCMV promoter in 
its plasmid backbone in producer cells, a plasmid expressing eGFP under the control of the 
hCMV promoter was also included in this experiment. Also, the promoterless plasmid 
pEGFP1 was included, to assess any background fluorescence. The resulting constructs 
were subsequently used to transfect a variety of tumour and non-tumour cell lines. Generally, 
cell lines were chosen according to published results, i.e. when a promoter has previously 
been tested in a particular cell line, this cell line, if available, was used. The used cell lines 
were HEK-293 (293), HeLa, NIH-3T3 (NIH), the hepatic cancer cell lines HepG2 and HuH-7, 
the breast cancer cell lines MCF7 and T47D, the neuroblastoma cell lines Neuro2a and 
SHSY5Y, and the pancreatic cancer cell line Panc1. All cell lines are of human origin, except 
for the murine cell lines NIH and Neuro2a. Calcium phosphate coprecipitation was the 
preferred transfection technique for most cell lines (see chapter 3), only Neuro2a and 
SHSY5Y cells were transfected using the Lipofectamine 2000 kit (Invitrogen), according to 
the manufacturer's recommendations. See table 1 for an overview of the promoters, their cell 
selectivity, the expression vectors containing them and the cell lines they were employed in. 
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Promoter Expression 
vector 
Cell selectivity Employed cell lines 
hCMV pCMVeGFP ubiquitously active  293, HeLa, NIH, HepG2, 
MCF7, T47D, Panc1, HuH-7, 
Neuro2a, SHSY5Y 
mCMV pEGFP1-mCMV ubiquitously active  293, HeLa, NIH, HepG2, 
MCF7, T47D, Panc1, HuH-7, 
Neuro2a, SHSY5Y 
c-fos pEGFP1-cfos ubiquitously active  293, HeLa, NIH, HepG2 
EII-Pa1AT pEGFP1-E2 liver tissue  HepG2 
 293, HeLa 
AFP pEGFP1-AFP liver cancer  HepG2 
 293, HeLa 
CTP4 pEGFP1-CTP4 various cancers  HepG2, HuH-7 
 293, HeLa 
Midkine pEGFP1-MK various cancers  MCF7, T47D, Panc1, HuH7, 
Neuro2a, SHSY5Y 
 293 
c-erbB-2 pEGFP1-cerb breast and ovarian 
cancer 
 MCF7 
 293 
 
Table 1  Overview of heterologous promoters, the expression vectors outfitted with them, 
their expected cell selectivity and the cell lines they were tested in (expected promoter 
activity:  active,  inactive). 
 
 
Two days after transfection, FACS analysis was performed on a portion of the cells, while 
another portion was used to create populations of stably transfected cells. The pEGFP1 
backbone contains the neo resistance marker, and cells were subjected to selection with 400 
µg/ml G418 for three to five weeks. FACS analysis was performed again thereafter (Fig. 9). 
The entire population of SHSY5Y cells died within one day of selection, hence they are either 
very sensitive to this dose of G418, or no transfection took place. 
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Fig. 9  Transcriptional activity of heterologous promoters. A number of cancer and non-cancer cell 
lines of human and murine origin were transfected with the eGFP expression vector pEGFP1 under 
the control of the heterologous promoters. (A) Percentage of eGFP-positive cells and (B) MFI of cells 
after transient transfection. (C) Percentage of eGFP-positive cells and (D) MFI of cells after selection 
of stable populations. 
 
 
In most cases, the MFI was higher in transiently transfected than in stably transfected cells, 
which is to be expected as only a fraction of the plasmids brought into a cell by transfection 
are eventually integrated into the genome. 
Significant background fluorescence by the promoterless plasmid pEGFP1 could only be 
observed in transiently transfected cells.  
The promiscuous hCMV and mCMV promoters mediated considerable transgene expression 
in all cell lines. The hCMV promoter - which has been described to be predominantly active 
in human cells - exhibited especially low activity in stably transfected NIH cells, much less so 
than the mCMV promoter. That being said, the activity of the hCMV promoter in the human 
cell line HeLa was even lower. 
The c-fos promoter drove robust gene expression in all cell lines tested, although it did not 
reach the expression levels of the mCMV promoter. 
Both the CTP4 and EII-Pa1AT promoters exhibited the desired strength and cell selectivity. 
In the liver-derived, β-catenin deregulated cell line HepG2, they achieved expression levels 
on par with the mCMV promoter, while being virtually inactive in 293 and HeLa cells. The 
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CTP4 promoter also showed some activity in HuH-7 cells, which are not known to be 
deregulated for β-catenin, but, again, only in transient assays.  
Both the MK and the c-erbB-2 promoters, which have been described to be tumour-selective, 
appeared to be equally active in 293 as in tumour cells, and the transgene expression levels 
they mediated in stably transfected cells were generally four times lower than those of the 
CTP4 or EII-Pa1AT promoter in permissive cell lines. 
The AFP promoter was more active in HepG2 than in 293 or HeLa cells, but the absolute 
expression levels were very low: In HepG2 cells, the activity of the AFP promoter was about 
one order of magnitude lower than that of the CTP4 or E2-Pa1AT promoter. 
 
Based on these results, the c-fos, CTP4 and EII-Pa1AT promoters, along with the mCMV 
promoter, were chosen as the subjects of further research, to be evaluated in the context of 
an RCR vector.  
 
 
2.2 Replication kinetics of an RCR vector under the control of the c-fos promoter 
 
For the evaluation of vectors with the mCMV, EII-Pa1AT and CTP4 promoters, as well as the 
parental vector ACE-GFP, see chapter 3. 
 
The c-fos promoter was inserted into the 3' U3 region of the replication-competent, MLV 
based vector ACE-GFP. Replication of this vector in producer cells is driven by the hCMV 
promoter in its plasmid backbone, but during reverse transcription, the promoter in the 3' LTR 
is copied to the 5' LTR and drives viral gene expression in infected cells. Instead of replacing 
the entire MLV promoter in the 3' LTR by the heterologous promoter, however, the so-called 
TATA fusion (TF) design was employed, whereby only a portion of the wild-type promoter, up 
to the 5' border of the TATA box, was removed and replaced with the corresponding 
sequence of the c-fos promoter, form its 5' end to the 5' border of its TATA box. The resulting 
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vector, termed cfos-TF, retained the MLV TATA box, a design which has proven superior to a 
full replacement of the wild-type promoter (Logg CR, 2002) (Fig. 10). 
 
 
 
Fig. 10  Design of the RCR vector cfos-TF. A large portion of the 3`U3 region of the MLV vector ACE-
GFP was replaced by the corresponding sequence of the c-fos promoter. 
 
 
In order to evaluate the replication kinetics and cell selectivity of cfos-TF, 293 cells were 
transiently transfected with the vector construct and virus-containing supernatant was 
harvested two days later. The supernatant was subsequently used to infect 293, HeLa, NIH 
and HepG2 cells. The cells were passaged every 3 to 4 days and FACS analysis was 
performed at each passage. Over a course of 19 days, cfos-TF spread very little  in any cell 
line, infecting 20% of the cell population at the most, and exhibited only low eGFP expression 
levels (Fig. 11).  
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Fig. 11  Replication kinetics of cfos-TF. 293, HeLa, NIH and HepG2 cells were infected with virus 
harvested from transiently transfected 293 cells. The infected cells were passaged every 3 to 4 days 
and FACS analysis was performed at each passage. (A) Percentage of eGPF-positive cells and (B) 
MFI of infected cells over a course of 19 days. 
 
 
It was decided to concentrate any further research on the CTP4, EII-Pa1AT and mCMV 
promoters. 
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4 Discussion and further development 
 
In this study, it was demonstrated that RCR vectors in which the wild-type promoter was 
replaced with the CTP4 or the EII-Pa1AT promoter exhibit robust transgene expression 
levels and rapid spread in cell culture, all in a tumour- or tissue-selective manner. But these 
promoters are only two of a larger set of candidate promoters, which also included the 
cancer-selective c-erbB-2, MK, and AFP promoters, as well as the promiscuous c-fos and 
mCMV promoters. 
 
In order to assess their strength and cell selectivity, the promoters were incorporated into the 
promoterless expression vector pEGFP1 and the resulting constructs were used to transfect 
a range of cell lines both transiently and stably (Fig. 9).  
Compared to the hCMV promoter, the mCMV promoter appears to be more evenly active in 
the cell lines used here, which may suggest that the mCMV promoter is better suited as a 
ubiquitously active promoter for comparative studies. However, such a conclusion probably 
cannot be drawn firmly from just this one experiment. In any case, the mCMV promoter was 
more active than the hCMV promoter in the murine cell line NIH, especially in stably 
transfected cells, which is in accordance with published data (Addison CL, 1997). 
Both the c-erbB-2 and the MK promoter appear to be comparatively weak and, most notably, 
as active in 293 cells as in cancer cells. An explanation for the unexpected activity of the MK 
promoter in 293 cells could be that the 600 bp fragment of this promoter used in the 
transfected construct lacks distal regulatory sequences of the full-length promoter. These 
regulatory elements may normally suppress the activity of the MK promoter in non-
permissive cells. On the other hand, although the MK promoter is generally described as only 
weakly active in adult normal tissues, considerable MK expression in kidney cells has been 
reported (Kubo S, 2010) (Muramatsu T., 1993). 
The proximal AFP promoter has already been shown to be relatively weak (Ido A, 1995) and 
the results of the current study do not prove otherwise. Although the AFP promoter appears 
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to be liver-selective, the expression levels it mediates remain low. Therefore, it was planned 
to fuse the HBV enhancer II to the AFP promoter, an enhancer which - as a part of the EII-
Pa1AT hybrid promoter - boosted the strength of the Pa1AT promoter considerably while 
retaining its liver selectivity (Kramer MG, 2003). Unfortunately, the cloning procedures were 
unsuccessful and this project was eventually abandoned due to time constraints. 
 
The c-fos promoter conferred considerable levels of transgene expression to pEGFP1 in 
transfected cells, yet as the promoter of the RCR vector cfos-TF, the transgene expression 
levels and vector spread it mediated were negligible (Fig. 11). The c-fos promoter is known 
to be an inducible one, and has been shown to be fully induced by cell culture medium 
supplemented with 10% FCS (Johansen FE, 1994). The cells transfected or infected with 
pEGFP1-cfos or cfos-TF, respectively, were all maintained in such conditions. 
By the time cfos-TF was tested, it was already apparent that TR vectors, as a rule, performed 
worse than TF vectors, hence no cfos-TR vector was ever created. It is not unthinkable, 
though, that in the case of the c-fos promoter the removal of its TATA box and the portion 
downstream of it deprived the promoter of a sequence vital for proper function. 
 
The activity of the CTP4, EII-Pa1AT and MK promoters was later evaluated in a similar, but 
semi-replicative vector (sRCR) by Andrea Wolkerstorfer (Wolkerstorfer A, 2007). This vector 
was based on Moloney-MLV and lacked the gag and pol genes. A cassette consisting of an 
eGFP-neomycin gene preceded by the Food and mouth disease virus (FMDV) 2A protease 
sequence was fused to the end of the env gene. Utilisation of the 2A sequence led to an up 
to three-fold increase in infectivity compared to vectors using the (longer) EMCV IRES. 
Furthermore, insertion of the Woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE) downstream of the transgene cassette doubled the transgene expression 
levels in transfected cells. 
In addition to creating TF and TR sRCR vectors with the heterologous promoters, 
Wolkerstorfer also developed an optimised TR (TRopt) design, whereby the TSS of the 
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heterologous promoter was placed in the same position as the TSS in wild-type MLV. This 
design is reminiscent of similar vectors created by Kasahara' s workgroup (Logg CR, 2002), 
which, unfortunately, offered no improvement compared to "traditional" TR vectors. 
Promoter strength and selectivity was tested by infection of HepG2 and NIH cells with the 
sRCR vectors. In HepG2 cells, the MFI mediated by the vectors containing the CTP4 or the 
EII-Pa1AT promoter was about six to ten times higher than in NIH cells. The sRCR vectors 
containing the MK promoter showed no clear tissue selectivity, and generally low expression 
levels. They were therefore excluded from further investigation. 
Replication kinetics of the sRCR vectors were evaluated by infection of Gag-Pol expressing 
293 (293gp) and HepG2 (HepG2gp) cells. The vectors replicated markedly faster in 
HepG2gp than in 293gp cells, but there was no clear difference in performance between TF, 
TR and TRopt vectors:  Amongst the vectors under the control of the CTP4 promoter, the TF 
vector spread the fastest, while amongst the vectors with the EII-Pa1AT promoter, the TRopt 
vector spread the fastest. Generally, these semi-replicative TR and TRopt vectors performed 
better than replication-competent TR vectors , and it was hypothesised that the excess 
quantities of Gag and Pol proteins provided in trans in the semi-packaging cells 
compensated for the weakness of the promoters. This would be in accordance with the 
results of the present study, which demonstrated that production of nascent virions, which 
can easily be affected by Gag and Pol levels, is reduced in TR as compared to TF vectors, 
while eGFP expression levels and infectivity are not. Wolkerstorfer showed that, in fact, the 
RCR vector E2-TR exhibited more robust spread in HepG2gp cells than in HepG2 cells, 
while the RCR vector CTP4-TR, on the other hand, spread as little in HepG2gp cells as in 
HepG2 cells. 
 
Retroviral vectors were the first vectors to be used in gene therapy, but now their use is 
declining, not least due to safety concerns. Their most striking advantage, the ability to stably 
integrate into the host's chromosome, can lead to insertional mutagenesis (Edelstein ML, 
2007). And yet the utility of retroviral vectors should not be dismissed. Further research on 
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the mechanisms of integration might give us clues as to how to improve their safety. 
Regarding replication-competent retroviral vectors, they could easily find their place in cancer 
gene therapy. Reliable targeting of the vector to cancer cells, which are subsequently 
destroyed, could make insertional mutagenesis less of an issue. The present study, as well 
as the works of Wolkerstorfer, Kasahara and many others, show that RCR vectors are still 
powerful tools for gene therapy. 
  
52 
 
 
5  References 
 
 
Addison CL, Hitt M, Kunsken D, Graham FL. 1997. Comparison of the human versus 
murine cytomegalovirus immediate early gene promoters for transgene expression by 
adenoviral vectors. s.l. : J Gen Virol. 1997 Jul;78 ( Pt 7):1653-61., 1997. 
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza 
S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-
Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, B. 
2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. s.l. : N 
Engl J Med. 2009 Jan 29;360(5):447-58., 2009. 
Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, 
Tabucchi A, Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo 
MG, Bordignon C. 2002. Correction of ADA-SCID by stem cell gene therapy combined with 
nonmyeloablative conditioning. s.l. : Science. 2002 Jun 28;296(5577):2410-3., 2002. 
Akbulut H, Tang Y, Akbulut KG, Maynard J, Zhang L, Deisseroth A. 2006. Antitumor 
immune response induced by i.t. injection of vector-activated dendritic cells and 
chemotherapy suppresses metastatic breast cancer. s.l. : Mol Cancer Ther. 2006 
Aug;5(8):1975-85., 2006. 
Bakin AV, Curran T. 1999. Role of DNA 5-methylcytosine transferase in cell transformation 
by fos. s.l. : Science. 1999 Jan 15;283(5400):387-90., 1999. 
Berlioz C, Darlix JL. 1995. An internal ribosomal entry mechanism promotes translation of 
murine leukemia virus gag polyprotein precursors. s.l. : J Virol. 1995 Apr;69(4):2214-22., 
1995. 
Bi JX, Buhr P, Zeng AP, Wirth M. 2003. Human c-fos promoter mediates high-level, 
inducible expression in various mammalian cell lines. s.l. : Biotechnol Bioeng. 2003 Mar 
30;81(7):848-54., 2003. 
Bolinger C, Boris-Lawrie K. 2009. Mechanisms employed by retroviruses to exploit host 
factors for translational control of a complicated proteome. s.l. : Retrovirology. 2009 Jan 
24;6:8., 2009. 
Butsch M, Boris-Lawrie K. 2002. Destiny of unspliced retroviral RNA: ribosome and/or 
virion? s.l. : J Virol. 2002 Apr;76(7):3089-94., 2002. 
Cao G, Kuriyama S, Gao J, Nakatani T, Chen Q, Yoshiji H, Zhao L, Kojima H, Dong Y, 
Fukui H, Hou J. 2001. Gene therapy for hepatocellular carcinoma based on tumour-
selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a 
housekeeping gene promoter. s.l. : Eur J Cancer. 2001 Jan;37(1):140-7., 2001. 
Cao G, Kuriyama S, Tsujinoue H, Chen Q, Mitoro A, Qi Z. 2000. A novel approach for 
inducing enhanced and selective transgene expression in hepatocellular-carcinoma cells. 
s.l. : Int J Cancer. 2000 Jul 15;87(2):247-52., 2000. 
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, 
Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. 2000. Gene 
therapy of human severe combined immunodeficiency (SCID)-X1 disease. s.l. : Science. 
2000 Apr 28;288(5466):669-72., 2000. 
Charneau P, Alizon M, Clavel F. 1992. A second origin of DNA plus-strand synthesis is 
required for optimal human immunodeficiency virus replication. s.l. : J Virol. 1992 
May;66(5):2814-20., 1992. 
Coffin JM, Hughes SH, Varmus HE. 1997. Retroviruses. s.l. : Cold Spring Harbour 
Laboratory Press, 1997. 
Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J, Glimm 
H, Gyapay G, Prum B, Fraser CC, Fischer N, Schwarzwaelder K, Siegler ML, de Ridder 
D, Pike-Overzet K, Howe SJ, Thrasher AJ, Wagemaker G, Abel U, Staal FJ, Delabesse 
53 
 
E, Villeva. 2007. Vector integration is nonrandom and clustered and influences the fate of 
lymphopoiesis in SCID-X1 gene therapy. s.l. : J Clin Invest. 2007 Aug;117(8):2225-32., 2007. 
Dorsch-Häsler K, Keil GM, Weber F, Jasin M, Schaffner W, Koszinowski UH. 1985. A 
long and complex enhancer activates transcription of the gene coding for the highly abundant 
immediate early mRNA in murine cytomegalovirus. s.l. : Proc Natl Acad Sci U S A. 1985 
Dec;82(24):8325-9., 1985. 
Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M, Wood J, Martiny-
Baron G, Unger C, Marmé D. 2000. Effects of PTK787/ZK 222584, a specific inhibitor of 
vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, 
vessel density, and blood flow in a murine renal cell carcinoma model. s.l. : Cancer Res. 
2000 Sep 1;60(17):4819-24., 2000. 
Edelstein ML, Abedi MR, Wixon J. 2007. Gene therapy clinical trials worldwide to 2007--an 
update. s.l. : J Gene Med. 2007 Oct;9(10):833-42., 2007. 
European Society of Gene Therapy (ESGT). 2006. One of three successfully treated CGD 
patients in a Swiss-German gene therapy trial died due to his underlying disease: A position 
statement from the European Society of Gene Therapy (ESGT). s.l. : J Gene Med. 2006 
Dec;8(12):1435., 2006. 
Ferrua F, Brigida I, Aiuti A. 2010. Update on gene therapy for adenosine deaminase-
deficient severe combined immunodeficiency. s.l. : Curr Opin Allergy Clin Immunol. 2010 
Dec;10(6):551-6., 2010. 
Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, 
Merli M, Magagnoli G, Balladelli A, Picci P. 1998. C-myc and c-fos in human 
osteosarcoma: prognostic value of mRNA and protein expression. s.l. : Oncology. 1998 Nov-
Dec;55(6):556-63., 1998. 
Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, 
Von Kalle C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, 
Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ. 2004. Gene therapy of X-linked 
severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. s.l. : 
Lancet. 2004 Dec 18-31;364(9452):2181-7., 2004. 
Gillet JP, Macadangdang B, Fathke RL, Gottesman MM, Kimchi-Sarfaty C. 2009. The 
development of gene therapy: from monogenic recessive disorders to complex diseases 
such as cancer. s.l. : Methods Mol Biol. 2009;542:5-54., 2009. 
Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, 
Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debré M, Casanova 
JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. 2010. Efficacy 
of gene therapy for X-linked severe combined immunodeficiency. s.l. : N Engl J Med. 2010 
Jul 22;363(4):355-64., 2010. 
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch 
P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen 
JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-
Lyonnet D,. 2003. LMO2-associated clonal T cell proliferation in two patients after gene 
therapy for SCID-X1. s.l. : Science. 2003 Oct 17;302(5644):415-9., 2003. 
Han JJ, Mhatre AN, Wareing M, Pettis R, Gao WQ, Zufferey RN, Trono D, Lalwani AK. 
1999. Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene 
transfer vector. s.l. : Hum Gene Ther. 1999 Jul 20;10(11):1867-73., 1999. 
Hashimoto T, Gibbs D, Lillo C, Azarian SM, Legacki E, Zhang XM, Yang XJ, Williams 
DS. 2007. Lentiviral gene replacement therapy of retinas in a mouse model for Usher 
syndrome type 1B. s.l. : Gene Ther. 2007 Apr;14(7):584-94. Epub 2007 Feb 1., 2007. 
Hiraoka K, Kimura T, Logg CR, Kasahara N. 2006. Tumor-selective gene expression in a 
hepatic metastasis model after locoregional delivery of a replication-competent retrovirus 
vector. s.l. : Clin Cancer Res. 2006 Dec 1;12(23):7108-16., 2006. 
Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, 
Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, Gilmour KC, Adams S, 
Thornhill SI, Parsley KL, Staal FJ, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, 
Kinnon C, Ancliff P,. 2008. Insertional mutagenesis combined with acquired somatic 
54 
 
mutations causes leukemogenesis following gene therapy of SCID-X1 patients. s.l. : J Clin 
Invest. 2008 Sep;118(9):3143-50., 2008. 
Hu E, Mueller E, Oliviero S, Papaioannou VE, Johnson R, Spiegelman BM. 1994. 
Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent 
pathways for gene expression stimulated by growth factors or oncogenes. s.l. : EMBO J. 
1994 Jul 1;13(13):3094-103., 1994. 
Huang PI, Chang JF, Kirn DH, Liu TC. 2009. Targeted genetic and viral therapy for 
advanced head and neck cancers. s.l. : Drug Discov Today. 2009 Jun;14(11-12):570-8. Epub 
2009 Mar 17., 2009. 
Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, 
Nagataki S. 1995. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes 
simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene 
promoter. s.l. : Cancer Res. 1995 Jul 15;55(14):3105-9., 1995. 
Johansen FE, Prywes R. 1994. Two pathways for serum regulation of the c-fos serum 
response element require specific sequence elements and a minimal domain of serum 
response factor. s.l. : Mol Cell Biol. 1994 Sep;14(9):5920-8., 1994. 
Katen LJ, Januszeski MM, Anderson WF, Hasenkrug KJ, Evans LH. 2001. Infectious 
entry by amphotropic as well as ecotropic murine leukemia viruses occurs through an 
endocytic pathway. s.l. : J Virol. 2001 Jun;75(11):5018-26., 2001. 
Kay MA. 2011. State-of-the-art gene-based therapies: the road ahead. s.l. : Nat Rev Genet. 
2011 May;12(5):316-28. Epub 2011 Apr 6., 2011. 
Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR, Kasahara N, 
Bochner BH. 2007. Highly efficient gene delivery for bladder cancers by intravesically 
administered replication-competent retroviral vectors. s.l. : Clin Cancer Res. 2007 Aug 
1;13(15 Pt 1):4511-8., 2007. 
Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR, Kasahara N, 
Bochner BH. 2007 (2). Delivery of replication-competent retrovirus expressing Escherichia 
coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine 
phosphate and suppresses the growth of bladder tumor xenografts. s.l. : Cancer Gene Ther. 
2007 Mar;14(3):279-86. Epub 2007 Jan 12., 2007 (2). 
Kimmelman J. 2008. The ethics of human gene transfer. s.l. : Nat Rev Genet. 2008 
Mar;9(3):239-44., 2008. 
Knipe DM, Howley PM. 2007. Fields Virology. s.l. : Lippincott Williams & Wilkins, a Walters 
Kluwer Business, 2007. 
Kohn DB, Candotti F. 2009. Gene therapy fulfilling its promise. s.l. : N Engl J Med. 2009 Jan 
29;360(5):518-21., 2009. 
Kramer MG, Barajas M, Razquin N, Berraondo P, Rodrigo M, Wu C, Qian C, Fortes P, 
Prieto J. 2003. In vitro and in vivo comparative study of chimeric liver-specific promoters. 
s.l. : Mol Ther. 2003 Mar;7(3):375-85., 2003. 
Kubo S, Kawasaki Y, Yamaoka N, Tagawa M, Kasahara N, Terada N, Okamura H. 2010. 
Complete regression of human malignant mesothelioma xenografts following local injection 
of midkine promoter-driven oncolytic adenovirus. s.l. : J Gene Med. 2010 Aug;12(8):681-92., 
2010. 
Kumar S, Walia V, Ray M, Elble RC. 2007. p53 in breast cancer: mutation and 
countermeasures. s.l. : Front Biosci. 2007 May 1;12:4168-78., 2007. 
Lafemina RL, Hayward GS. 1988. Differences in cell-type-specific blocks to immediate early 
gene expression and DNA replication of human, simian and murine cytomegalovirus. s.l. : J 
Gen Virol. 1988 Feb;69 ( Pt 2):355-74., 1988. 
Lazarevich. 2000. Molecular mechanisms of alpha-fetoprotein gene expression. s.l. : 
Biochemistry (Mosc). 2000 Jan;65(1):117-33., 2000. 
LeBlanc JJ, Beemon KL. 2004. Unspliced Rous sarcoma virus genomic RNAs are 
translated and subjected to nonsense-mediated mRNA decay before packaging. s.l. : J Virol. 
2004 May;78(10):5139-46., 2004. 
Lederberg, J. 1963. Biological future of man. London: Churchill, 265 : In: Wolstenholme, G., 
ed. Man and His Future, 1963. 
55 
 
Lewinski MK, Yamashita M, Emerman M, Ciuffi A, Marshall H, Crawford G, Collins F, 
Shinn P, Leipzig J, Hannenhalli S, Berry CC, Ecker JR, Bushman FD. 2006. Retroviral 
DNA integration: viral and cellular determinants of target-site selection. s.l. : PLoS Pathog. 
2006 Jun;2(6):e60. Epub 2006 Jun 23., 2006. 
Lipinski KS, Djeha AH, Ismail T, Mountain A, Young LS, Wrighton CJ. 2001. High-level, 
beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. 
s.l. : Mol Ther. 2001 Oct;4(4):365-71., 2001. 
Lipinski KS, Djeha HA, Gawn J, Cliffe S, Maitland NJ, Palmer DH, Mountain A, Irvine 
AS, Wrighton CJ. 2004. Optimization of a synthetic beta-catenin-dependent promoter for 
tumor-specific cancer gene therapy. s.l. : Mol Ther. 2004 Jul;10(1):150-61., 2004. 
Liu XF, Yan S, Abecassis M, Hummel M. 2008. Establishment of murine cytomegalovirus 
latency in vivo is associated with changes in histone modifications and recruitment of 
transcriptional repressors to the major immediate-early promoter. s.l. : J Virol. 2008 
Nov;82(21):10922-31. Epub 2008 Aug 27., 2008. 
Logan CY, Nusse R. 2004. The Wnt signaling pathway in development and disease. s.l. : 
Annu Rev Cell Dev Biol. 2004;20:781-810., 2004. 
Logg CR, Logg A, Matusik RJ, Bochner BH, Kasahara N. 2002. Tissue-specific 
transcriptional targeting of a replication-competent retroviral vector. s.l. : J Virol. 2002 
Dec;76(24):12783-91., 2002. 
Logg CR, Tai CK, Logg A, Anderson WF, Kasahara N. 2001. A uniquely stable replication-
competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. s.l. : 
Hum Gene Ther. 2001 May 20;12(8):921-32., 2001. 
Lund AH, Duch M, Pedersen FS. 2000. Selection of functional tRNA primers and primer 
binding site sequences from a retroviral combinatorial library: identification of new functional 
tRNA primers in murine leukemia virus replication. s.l. : Nucleic Acids Res. 2000 Feb 
1;28(3):791-9., 2000. 
MacDonald BT, Tamai K, He X. 2009. Wnt/beta-catenin signaling: components, 
mechanisms, and diseases. s.l. : Dev Cell. 2009 Jul;17(1):9-26., 2009. 
Mae M, O'Connor TP, Crystal RG. 2005. Gene transfer of the vascular endothelial growth 
factor receptor flt-1 suppresses pulmonary metastasis associated with lung growth. s.l. : Am 
J Respir Cell Mol Biol. 2005 Dec;33(6):629-35. Epub 2005 Sep 8., 2005. 
Maeda T, O-Wang J, Matsubara H, Asano T, Ochiai T, Sakiyama S, Tagawa M. 2001. A 
minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase 
gene confers selective cytotoxicity of human breast cancer cells to ganciclovir. s.l. : Cancer 
Gene Ther. 2001 Nov;8(11):890-6., 2001. 
Marshall E. 1999. Gene therapy death prompts review of adenovirus vector. s.l. : Science. 
1999 Dec 17;286(5448):2244-5., 1999. 
Mátrai J, Chuah MK, VandenDriessche T. 2010. Recent advances in lentiviral vector 
development and applications. s.l. : Mol Ther. 2010 Mar;18(3):477-90. Epub 2010 Jan 19., 
2010. 
Miyauchi M, Yoshida Y, Tada Y, Narita M, Maeda T, Bahar R, Kadomatsu K, Muramatsu 
T, Matsubara S, Nakagawara A, Sakiyama S, Tagawa M. 2001. Expression of herpes 
simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene 
confers selective cytotoxicity to ganciclovir in human carcinoma cells. s.l. : Int J Cancer. 2001 
Mar 1;91(5):723-7., 2001. 
Modlich U, Bohne J, Schmidt M, von Kalle C, Knöss S, Schambach A, Baum C. 2006. 
Cell-culture assays reveal the importance of retroviral vector design for insertional 
genotoxicity. s.l. : Blood. 2006 Oct 15;108(8):2545-53. Epub 2006 Jul 6., 2006. 
Muramatsu T. 2010. Midkine, a heparin-binding cytokine with multiple roles in development, 
repair and diseases. s.l. : Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(4):410-25., 2010. 
Muramatsu T. 1993. Midkine (MK), the product of a retinoic acid responsive gene, and 
pleiotrophin constitute a new protein family regulating growth and differentiation. s.l. : Int J 
Dev Biol. 1993 Mar;37(1):183-8., 1993. 
Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill 
A, Clairmont C, Sznol M. 2003. Pilot trial of genetically modified, attenuated Salmonella 
56 
 
expressing the E. coli cytosine deaminase gene in refractory cancer patients. s.l. : Cancer 
Gene Ther. 2003 Oct;10(10):737-44., 2003. 
Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, 
Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, 
Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer 
D, vo. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, 
augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. s.l. : Nat Med. 
2006 Apr;12(4):401-9. Epub 2006 Apr 2., 2006. 
Pauwels K, Gijsbers R, Toelen J, Schambach A, Willard-Gallo K, Verheust C, Debyser 
Z, Herman P. 2009. State-of-the-art lentiviral vectors for research use: risk assessment and 
biosafety recommendations. s.l. : Curr Gene Ther. 2009 Dec;9(6):459-74., 2009. 
Peng Z. 2005. Current status of gendicine in China: recombinant human Ad-p53. s.l. : Hum 
Gene Ther 16: 1016–1027, 2005. 
Pizzato M, Marlow SA, Blair ED, Takeuchi Y. 1999. Initial binding of murine leukemia virus 
particles to cells does not require specific Env-receptor interaction. s.l. : J Virol. 1999 
Oct;73(10):8599-611., 1999. 
Rainov NG, Ren H. 2003. Clinical trials with retrovirus mediated gene therapy--what have 
we learned? s.l. : J Neurooncol. 2003 Dec;65(3):227-36., 2003. 
Rodrigues T, Carvalho A, Carmo M, Carrondo MJ, Alves PM, Cruz PE. 2007. Scaleable 
purification process for gene therapy retroviral vectors. s.l. : J Gene Med. 2007 Apr;9(4):233-
43., 2007. 
Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, 
Lotze MT, Yang JC, Topalian SL, et al. 1990. Gene transfer into humans--immunotherapy 
of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by 
retroviral gene transduction. s.l. : N Engl J Med. 1990 Aug 30;323(9):570-8, 1990. 
Sakiyama S, Yu L, Tomizawa M, Shimada H, Kadomatsu K, Muramatsu T, Ikematsu S, 
Nakagawara A, Tagawa M. 2003. Utilization of the promoter region of the midkine gene as a 
tool to drive therapeutic genes in a tumor specific manner. s.l. : Adv Enzyme Regul. 
2003;43:57-66., 2003. 
Saller RM, Oztürk F, Salmons B, Günzburg WH. 1998. Construction and characterization 
of a hybrid mouse mammary tumor virus/murine leukemia virus-based retroviral vector. s.l. : 
J Virol. 1998 Feb;72(2):1699-703., 1998. 
Sharma A, Tandon M, Bangari DS, Mittal SK. 2009. Adenoviral vector-based strategies for 
cancer therapy. s.l. : Curr Drug ther. 2009 May 1;4(2):117-138., 2009. 
Shaulian E, Karin M. 2001. AP-1 in cell proliferation and survival. s.l. : Oncogene. 2001 Apr 
30;20(19):2390-400., 2001. 
Shi J, Zheng D. 2009. An update on gene therapy in China. s.l. : Curr Opin Mol Ther. 2009 
Oct;11(5):547-53, 2009. 
Shi YJ, Gong JP, Liu CA, Li XH, Mei Y, Mi C, Huo YY. 2004. Construction of a targeting 
adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP-producing 
hepatocarcinoma cell. s.l. : World J Gastroenterol. 2004 Jan 15;10(2):186-9., 2004. 
Shibata MA, Miwa Y, Miyashita M, Morimoto J, Abe H, Otsuki Y. 2005. Electrogene 
transfer of an Epstein-Barr virus-based plasmid replicon vector containing the diphtheria 
toxin A gene suppresses mammary carcinoma growth in SCID mice. s.l. : Cancer Sci. 2005 
Jul;96(7):434-40., 2005. 
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, 
Udove J, Ullrich A, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast 
and ovarian cancer. s.l. : Science. 1989 May 12;244(4905):707-12., 1989. 
Smith E, Redman RA, Logg CR, Coetzee GA, Kasahara N, Frenkel B. 2000. 
Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of 
cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes. s.l. : J Biol Chem. 2000 Jun 
30;275(26):19992-20001., 2000. 
Smith KR. 2004. Gene Therapy: The Potential Applicability of Gene Transfer Technology to 
the Human Germline. s.l. : Int J Med Sci. 2004;1(2):76-91. Epub 2004 Jun 1., 2004. 
Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin CA, 
Mahadevan LC, Arthur JS. 2003. MSK2 and MSK1 mediate the mitogen- and stress-
57 
 
induced phosphorylation of histone H3 and HMG-14. s.l. : EMBO J. 2003 Jun 2;22(11):2788-
97., 2003. 
Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, 
Krämer A, Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, 
Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, 
Kühlcke K, Schlegelb. 2010. Genomic instability and myelodysplasia with monosomy 7 
consequent to EVI1 activation after gene therapy for chronic granulomatous disease. s.l. : 
Nat Med. 2010 Feb;16(2):198-204. Epub 2010 Jan 24., 2010. 
Suzuki Y, Yang H, Craigie R. 2004. LAP2alpha and BAF collaborate to organize the 
Moloney murine leukemia virus preintegration complex. s.l. : EMBO J. 2004 Nov 
24;23(23):4670-8. Epub 2004 Oct 28., 2004. 
Tai CK, Logg CR, Park JM, Anderson WF, Press MF, Kasahara N. 2003. Antibody-
mediated targeting of replication-competent retroviral vectors. s.l. : Hum Gene Ther. 2003 
May 20;14(8):789-802., 2003. 
Tai CK, Wang W, Lai YH, Logg CR, Parker WB, Li YF, Hong JS, Sorscher EJ, Chen TC, 
Kasahara N. 2010. Enhanced efficiency of prodrug activation therapy by tumor-selective 
replicating retrovirus vectors armed with the Escherichia coli purine nucleoside 
phosphorylase gene. s.l. : Cancer Gene Ther. 2010 Sep;17(9):614-23. Epub 2010 May 14., 
2010. 
Tai CK, Wang WJ, Chen TC, Kasahara N. 2005. Single-shot, multicycle suicide gene 
therapy by replication-competent retrovirus vectors achieves long-term survival benefit in 
experimental glioma. s.l. : Mol Ther. 2005 Nov;12(5):842-51., 2005. 
Tardiff J, Krauter KS. 1998. Divergent expression of alpha1-protease inhibitor genes in 
mouse and human. s.l. : Nucleic Acids Res. 1998 Aug 15;26(16):3794-9., 1998. 
Teng CS. 2000. Protooncogenes as mediators of apoptosis. s.l. : Int Rev Cytol. 
2000;197:137-202., 2000. 
Thomas S, Hart DP, Xue SA, Cesco-Gaspere M, Stauss HJ. 2007. T-cell receptor gene 
therapy for cancer: the progress to date and future objectives. s.l. : Expert Opin Biol Ther. 
2007 Aug;7(8):1207-18., 2007. 
Vile RG, Russell SJ, Lemoine NR. 2000. Cancer gene therapy: hard lessons and new 
courses. s.l. : Gene Ther. 2000 Jan;7(1):2-8., 2000. 
Waltzer L, Bienz M. 1999. The control of beta-catenin and TCF during embryonic 
development and cancer. s.l. : Cancer Metastasis Rev. 1999;18(2):231-46., 1999. 
Wang SC, Hung MC. 2000. Transcriptional targeting of the HER-2/neu oncogene. s.l. : 
Drugs Today (Barc). 2000 Dec;36(12):835-43., 2000. 
Wang WJ, Tai CK, Kasahara N, Chen TC. 2003. Highly efficient and tumor-restricted gene 
transfer to malignant gliomas by replication-competent retroviral vectors. s.l. : Hum Gene 
Ther. 2003 Jan 20;14(2):117-27., 2003. 
Weber E, Anderson WF, Kasahara N. 2001. Recent advances in retrovirus vector-mediated 
gene therapy: teaching an old vector new tricks. s.l. : Curr Opin Mol Ther. 2001 Oct;3(5):439-
53., 2001. 
Wolkerstorfer A. 2007. Establishment of a semi-replicative vector system for the analysis of 
putative tissue/tumour specific promoters in vitro and in vivo. s.l. : University of Natural 
Resources and Life Sciences, Doctoral Thesis, 2007. 
Xu L, Mei M, Haskins ME, Nichols TC, O'donnell P, Cullen K, Dillow A, Bellinger D, 
Ponder KP. 2007. Immune response after neonatal transfer of a human factor IX-expressing 
retroviral vector in dogs, cats, and mice. s.l. : Thromb Res. 2007;120(2):269-80. Epub 2006 
Nov 7., 2007. 
Yamada K, Tsukahara T, Yoshino K, Kojima K, Agawa H, Yamashita Y, Amano Y, Hatta 
M, Matsuzaki Y, Kurotori N, Wakui K, Fukushima Y, Osada R, Shiozawa T, Sakashita K, 
Koike K, Kumaki S, Tanaka N, Takeshita T. 2009. Identification of a high incidence region 
for retroviral vector integration near exon 1 of the LMO2 locus. s.l. : Retrovirology. 2009 Sep 
2;6:79., 2009. 
Yamashita M, Emerman M. 2006. Retroviral infection of non-dividing cells: old and new 
perspectives. s.l. : Virology. 2006 Jan 5;344(1):88-93., 2006. 
58 
 
Yee JK. 1989. A liver-specific enhancer in the core promoter region of human hepatitis B 
virus. s.l. : Science. 1989 Nov 3;246(4930):658-61., 1989. 
Yu L, Hamada K, Namba M, Kadomatsu K, Muramatsu T, Matsubara S, Tagawa M. 
2004. Midkine promoter-driven suicide gene expression and -mediated adenovirus 
replication produced cytotoxic effects to immortalised and tumour cells. s.l. : Eur J Cancer. 
2004 Jul;40(11):1787-94., 2004. 
Yu L, Kamo S, Tagawa M. 2002. Identification of a minimal c-erbB-2 promoter region that 
mediates preferential expression of a linked foreign gene in human breast cancer cells. s.l. : 
Int J Oncol. 2002 Mar;20(3):607-10., 2002. 
Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. 1990. HIV-1 entry into 
quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. s.l. : 
Cell. 1990 Apr 20;61(2):213-22., 1990. 
Zhang H, Zhang Y, Spicer TP, Abbott LZ, Abbott M, Poiesz BJ. 1993. Reverse 
transcription takes place within extracellular HIV-1 virions: potential biological significance. 
s.l. : AIDS Res Hum Retroviruses. 1993 Dec;9(12):1287-96., 1993. 
Zhou S, Mody D, DeRavin SS, Hauer J, Lu T, Ma Z, Hacein-Bey Abina S, Gray JT, 
Greene MR, Cavazzana-Calvo M, Malech HL, Sorrentino BP. 2010. A self-inactivating 
lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human 
T cells. s.l. : Blood. 2010 Aug 12;116(6):900-8. Epub 2010 May 10., 2010. 
 
 
  
59 
 
6 Acknowledgements 
 
Principally, I would like to thank my supervisor Daniel Portsmouth, whose work of preparation 
made this study possible in the first place, and whose support and patience were invaluable 
for carrying it out and, last but not least, finishing it. 
 
My appreciation also goes to Walter Günzburg and Matthias Renner, who were my bosses 
but were, though masters of their trade, certainly not bossy. 
 
I also owe a Thank You to the lab technicians, most notably Reinhard Ertl and Magdalena 
Pusch, who never once complained when they needed to take care of my innumerable FACS 
samples late in the evening. 
 
Finally, my gratitude goes to all my colleagues at the Institute - Johannes Lengler and Beate 
Liehl, to name only a few - for their companionship and their advice, but most of all for the 
pleasant surrounding they all contributed to create. 
 
  
60 
 
7 Curriculum vitae 
 
Christian Metzl 
Date of birth: 31th March 1979 
Nationality: Austrian 
 
Education: 
1989 – 1997  Secondary school (AHS) in Eisenstadt, Austria 
1997 – 1999  Medical studies at the University of Vienna, Austria 
since 1999  Biology studies at the University of Vienna, Austria 
2004 – 2005  Diploma thesis at the Research Institute for Virology and Biomedicine, 
   University of Veterinary Medicine, Vienna, Austria 
 
Publication: 
Metzl C, Mischek D, Salmons B, Günzburg WH, Renner M, Portsmouth D.   
Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent 
retroviral vectors. 
J Virol. 2006 Jul;80(14):7070-8. 
 
Research presentation: 
Metzl C, Mischek D, Paar M, Portsmouth D, Günzburg WH, Salmons B et al. 
Transcriptionally regulated, replication-competent retroviral vectors for cancer gene therapy 
3rd workshop "Viral Vectors" of the "Gesellschaft für Virologie" and 12th annual meeting of the 
German Society for Gene Therapy, Würzburg, Germany, 2005 (oral presentation) 
 
